Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Cor (NQ: CTSO )

0.8100 -0.0117 (-1.42%)
Streaming Delayed Price Updated: 11:25 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,453
Open 0.8302
Bid (Size) 0.8100 (9)
Ask (Size) 0.8630 (2)
Prev. Close 0.8217
Today's Range 0.8100 - 0.8471
52wk Range 0.7820 - 4.290
Shares Outstanding 54,293,555
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
From CytoSorbents
Via GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-24.30%
-24.30%
1 Month
-10.72%
-10.72%
3 Month
-8.99%
-8.99%
6 Month
-54.24%
-54.24%
1 Year
-70.00%
-70.00%

More News

Read More
Recap: CytoSorbents Q4 Earnings
Via Benzinga
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
From CytoSorbents
Via GlobeNewswire
A Preview Of CytoSorbents's Earnings
Via Benzinga
What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents
Via Benzinga
Recap: CytoSorbents Q3 Earnings
Via Benzinga
Earnings Scheduled For March 14, 2024
Via Benzinga
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
From CytoSorbents
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
From CytoSorbents
Via GlobeNewswire
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Gold Moves Lower; US Crude Stocks Decline Last Week
Via Benzinga
Topics Stocks
Exposures US Equities
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Down 1%; US Wholesale Inventories Fall In November
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Gains 50 Points; US Jobless Claims Rise To 218,000
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
From CytoSorbents
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.